Teva Pharmaceuticals (pty) Limited

Teva Pharmaceuticals (Pty) Limited is a subsidiary of Teva Pharmaceutical Industries Ltd., a global leader in generic and specialty medicines. Established in 1901 in Jerusalem, Teva has expanded its operations worldwide, including a significant presence in South Africa. The South African subsidiary is headquartered at 1st Floor, Building 3, Maxwell Office Park, Magwa Crescent West, Waterfall City, Midrand, Gauteng. (teva.co.za) As a pharmaceutical importer and buyer, Teva Pharmaceuticals (Pty) Limited plays a crucial role in the South African pharmaceutical distribution network, ensuring the availability of a diverse range of medicines to meet the country's healthcare needs.

Teva Pharmaceuticals (Pty) Limited operates a comprehensive distribution network within South Africa, with its central office located in Midrand, Gauteng. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, Teva's global infrastructure supports efficient distribution channels. The company's extensive supply chain ensures that medicines are delivered promptly to various regions across South Africa, facilitating access to essential healthcare products nationwide.

In the South African pharmaceutical supply chain, Teva Pharmaceuticals (Pty) Limited functions primarily as a pharmaceutical importer and buyer. By sourcing finished pharmaceutical formulations from international suppliers, including India, Teva ensures the availability of a wide array of medicines in the local market. This role is vital in maintaining a steady supply of both generic and specialty medicines, thereby contributing to the overall healthcare infrastructure of South Africa.

Teva Pharmaceuticals (Pty) Limited's sourcing strategy reveals a notable concentration in its supplier base. The company has imported finished pharmaceutical formulations from two Indian suppliers:

• ADCOCK INGRAM LIMITED: $358,000 across 9 shipments, accounting for 78.6% of the total import value.
• CENTAUR PHARMACEUTICALS PRIVATE LIMITED: $98,000 across 2 shipments, representing 21.4% of the total import value.

This concentration indicates a strategic choice to maintain strong relationships with a select number of suppliers, potentially ensuring consistency in product quality and supply reliability. However, such dependency also poses risks, as any disruptions with these suppliers could significantly impact Teva's ability to meet market demand.

The resilience of Teva Pharmaceuticals (Pty) Limited's Indian supply chain is influenced by its reliance on a limited number of suppliers. While this focused approach may streamline operations, it also means that the company has limited backup suppliers to mitigate potential disruptions. The diversity of formulations imported—11 unique products across two therapeutic categories—provides some level of flexibility. However, the heavy reliance on a few suppliers underscores the importance of robust contingency planning and maintaining strong supplier relationships to ensure a resilient supply chain.

Teva Pharmaceuticals (Pty) Limited's sourcing pattern, characterized by a concentrated supplier base, has strategic implications for its competitive position. This approach may lead to favorable terms and consistent product quality, enhancing Teva's market standing. For Indian exporters, this presents an opportunity to become alternative suppliers by meeting Teva's quality standards and supply requirements. Diversifying Teva's supplier base could also mitigate risks associated with over-reliance on a few partners, potentially leading to more competitive pricing and improved supply chain stability.

In South Africa, the South African Health Products Regulatory Authority (SAHPRA) is the primary body responsible for regulating medicines and related substances. SAHPRA operates under the Medicines and Related Substances Act, 101 of 1965, as amended, which provides the legislative framework for the control of medicines, medical devices, and related substances. This act outlines the requirements for the registration, importation, and distribution of pharmaceutical products within the country. (sahpra.org.za)

To import pharmaceutical products into South Africa, companies must obtain a license from SAHPRA. This license is issued to manufacturers, wholesalers, or distributors and is contingent upon adherence to acceptable quality assurance principles and good manufacturing and distribution practices. Recognized Good Manufacturing Practice (GMP) certifications, such as EU GMP, WHO GMP, or PIC/S, are typically required to ensure that imported medicines meet the necessary quality standards. Additionally, wholesale distribution authorization is mandatory for entities involved in the distribution of pharmaceutical products within South Africa. (sahpra.org.za)

Imported pharmaceutical products must undergo batch testing to confirm their quality, safety, and efficacy. Stability studies are also required to ensure that medicines maintain their intended quality throughout their shelf life. Labeling requirements include the use of official languages, with English being the primary language for labeling. Serialization mandates may apply to facilitate traceability and prevent counterfeit products from entering the market. These regulations are enforced by SAHPRA to protect public health and ensure the integrity of the pharmaceutical supply chain. (sahpra.org.za)

Between 2024 and 2026, South Africa has implemented several policy changes affecting pharmaceutical imports. These include stricter enforcement of GMP standards, updated labeling requirements to enhance patient safety, and the introduction of electronic tracking systems for imported medicines. These changes aim to improve the quality and safety of pharmaceutical products available in the South African market. Companies like Teva Pharmaceuticals (Pty) Limited must stay informed and compliant with these evolving regulations to maintain uninterrupted operations.

Teva Pharmaceuticals (Pty) Limited's focus on importing finished pharmaceutical formulations in the therapeutic categories of Analgesics & Antipyretics and Respiratory & OTC products aligns with market demand in South Africa. Analgesics and antipyretics are essential for managing pain and fever, conditions prevalent across various demographics. Respiratory and over-the-counter products address common ailments such as colds, coughs, and other respiratory issues, which are widespread in the region. This strategic product selection ensures that Teva meets the immediate healthcare needs of the South African population.

Teva Pharmaceuticals (Pty) Limited's sourcing strategy emphasizes the importation of generic drug formulations, primarily from India. This approach leverages India's established reputation for producing high-quality, cost-effective generic medicines. The focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market products that can be swiftly distributed within South Africa. This strategy aligns with Teva's global mission to provide accessible and affordable healthcare solutions.

Based on its product mix, Teva Pharmaceuticals (Pty) Limited serves multiple segments of the South African market. By importing both prescription and over-the-counter medicines, Teva caters to retail pharmacies, hospitals, and government tenders. The company's diverse product portfolio enables it to address a wide range of healthcare needs, positioning Teva as a versatile and integral player in the South African pharmaceutical distribution landscape.

There is a realistic opportunity for new Indian suppliers to enter Teva Pharmaceuticals (Pty) Limited's supply chain. The company's current sourcing pattern, characterized by a limited number of suppliers, suggests potential gaps that new entrants could fill. By meeting Teva's quality standards and regulatory requirements, Indian exporters can establish partnerships that enhance Teva's supply chain resilience and offer additional product options to the South African market.

Indian exporters aiming to supply Teva Pharmaceuticals (Pty) Limited and the South African market must adhere to several requirements. These include obtaining GMP certifications recognized by SAHPRA, such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with SAHPRA's import licensing regulations, quality assurance principles, and labeling standards is mandatory. Ensuring that products meet these criteria is essential for successful market entry and distribution within South Africa. (sahpra.org.za)

To establish a relationship with Teva Pharmaceuticals (Pty) Limited, Indian exporters should first ensure compliance with SAHPRA's regulatory requirements, including obtaining the necessary GMP certifications and import licenses. Engaging in direct communication with Teva's procurement department to understand their specific needs and quality standards is crucial. Participating in relevant tenders and submitting regulatory filings in a timely manner will facilitate the approval process. Setting realistic timelines and maintaining consistent communication will enhance the likelihood of a successful partnership.